SCHEMBL25877360

SCHEMBL25877360

COc1cc(C=O)c(Br)c(OCc2ccccc2)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
ERN1 O75460 3/20 0.47
TUBB1 Q9H4B7 1/20 0.42
BCHE P06276 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPK1 P28482 1/20 0.41
PRKDC P78527 1/20 0.41
SMPD1 P17405 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24140612 0.90 ALDH1A1 (0.51) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL9860631 0.88 MAPT (0.50) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL25877366 0.88 ERN1 (0.50) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL24140920 0.86 SMN1; SMN2 (0.50) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL25877759 0.85 PTPN1 (0.45) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL25877825 0.85 ERN1 (0.47) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL25877356 0.85 ERN1 (0.49) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL25877626 0.84 MAPT (0.48) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL25877383 0.84 ERN1 (0.46) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL24140500 0.83 ERN1 (0.50) MAPTALDH1A1SMN1; SMN2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B MAPT 3694/4885ALDH1A1 1451/4885SMN1; SMN2 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.